luismmolina Shares of European T-Cell receptor therapy concern Immatics N.V. (NASDAQ:IMTX) have traded predominantly below their initial trade on the NASDAQ in 2020 due to a dearth of clinical data. That drought will end in 2024 with readouts anticipated on all four clinical candidates, as well as the expected initiation of a pivotal trial for…
luismmolina Investment Overview Immatics (NASDAQ:IMTX), based in Tuebingen, Germany, achieved its Nasdaq listing in 2020, via a business combination with Arya Sciences Acquisition Corp, a special purpose acquisition company (SPAC) sponsored by Perceptive Advisors. According to Harvard Business Review: A SPAC is a publicly traded corporation with a two-year life span formed with the sole…
phuttaphat tipsana/iStock via Getty Images Thesis overview Evaxion (EVAX) aspires to use artificial intelligence (AI) to design vaccines for cancer immunotherapy, as well as for infectious diseases. EVAX claims being more advanced than competition because it has been constantly developing and improving its models for 15 years. Additionally, EVAX has in-house capability to validate novel…
Pasha Pechenkin Last summer, I believed that Aspen Aerogels (NYSE:ASPN) was not insulating investors from the cold, like its products are supposed to do. The company after talked about its promise, but that did not convince investors as it took a long time to show up in the results. With the business having seen runaway…
The exterior of an AutoZone store. TennesseePhotographer In investing, there is no one-size-fits-all approach. Some investors may prefer growth, some may prefer value/dividends, and others may take a passive approach and buy index funds. These are all strategies that have made many investors rich over the long run. Today, I am going to diverge from…
The Washington Post/The Washington Post via Getty Images Authority without wisdom is like a heavy axe without an edge, fitter to bruise than polish.”― Anne Bradstreet. It has been just over a year since we last took a look at a small cap name called Wrap Technologies, Inc. (NASDAQ:WRAP). When we last highlighted this company,…
champc Reviewing 2023 results for the major asset classes reflects a long list of winners, with one conspicuous downside outlier: commodities. Amid widespread gains in global markets last year, the red ink in raw materials stands out. Does that create the setup for a rebound in 2024? I considered the possibility a month ago, but…
urzine/iStock via Getty Images Clarus (NASDAQ:CLAR) sells outdoor equipment in the United States as well as internationally. The company operates under three segments – Outdoor with the Black Diamond, ClimbOn, and PIEPS brands, soon-to-be-sold Precision Sport with Sierra Bullets and Barnes Bullets brands, and Adventure with Rhino-Rack, MAXTRAX and TRED. Clarus November Investor Presentation Clarus’…
Phiromya Intawongpan “Zero days until expiration” options, or ODTEs, have become a popular way to day trade markets. ODTEs are options that are issued and expire on the same trading day. The proliferation of derivatives trading as costs have come down, and as investors continue to shorten their holding periods, naturally led to a sprawling…
Shutter2U/iStock via Getty Images Intro Relmada Therapeutics (NASDAQ:RLMD) is advancing its NMDA antagonist, REL-1017 (esmethadone), as a novel antidepressant for the treatment of major depressive disorder (MDD). After reporting strongly positive Phase 2 results in late 2019, the company announced the failure of two Phase 3 trials in late 2022, cratering the stock from $1+…
urbancow Fastenal Company (NASDAQ:FAST) manufactures and sells industrial and construction supplies to businesses. The company has demonstrated very impressive long-term financials. As the company’s valuation reflects an excessively good performance from the company, though, I have a sell-rating for the stock at the current price. The Company Fastenal provides industrial supplies – the company’s offering…